JP7272952B2 - 内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法 - Google Patents

内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法 Download PDF

Info

Publication number
JP7272952B2
JP7272952B2 JP2019530105A JP2019530105A JP7272952B2 JP 7272952 B2 JP7272952 B2 JP 7272952B2 JP 2019530105 A JP2019530105 A JP 2019530105A JP 2019530105 A JP2019530105 A JP 2019530105A JP 7272952 B2 JP7272952 B2 JP 7272952B2
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
genome editing
protein
editing system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019530105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536462A5 (enExample
JP2019536462A (ja
Inventor
アリ イー． フリートラント，
ハリハラン ジャヤラム，
ベレット イーサン スタインバーグ，
Original Assignee
エディタス・メディシン、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エディタス・メディシン、インコーポレイテッド filed Critical エディタス・メディシン、インコーポレイテッド
Publication of JP2019536462A publication Critical patent/JP2019536462A/ja
Publication of JP2019536462A5 publication Critical patent/JP2019536462A5/ja
Priority to JP2022208855A priority Critical patent/JP2023052089A/ja
Application granted granted Critical
Publication of JP7272952B2 publication Critical patent/JP7272952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019530105A 2016-12-05 2017-12-05 内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法 Active JP7272952B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022208855A JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430154P 2016-12-05 2016-12-05
US62/430,154 2016-12-05
US201762503640P 2017-05-09 2017-05-09
US62/503,640 2017-05-09
PCT/US2017/064720 WO2018106693A1 (en) 2016-12-05 2017-12-05 SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022208855A Division JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法

Publications (3)

Publication Number Publication Date
JP2019536462A JP2019536462A (ja) 2019-12-19
JP2019536462A5 JP2019536462A5 (enExample) 2021-01-21
JP7272952B2 true JP7272952B2 (ja) 2023-05-12

Family

ID=60972337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530105A Active JP7272952B2 (ja) 2016-12-05 2017-12-05 内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法
JP2022208855A Withdrawn JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022208855A Withdrawn JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源ＤＮＡのワンショットガイドＲＮＡ（ｏｇＲＮＡ）標的化のためのシステムおよび方法

Country Status (9)

Country Link
US (6) US9963719B1 (enExample)
EP (1) EP3548614A1 (enExample)
JP (2) JP7272952B2 (enExample)
KR (1) KR102604903B1 (enExample)
CN (1) CN110168084A (enExample)
AU (1) AU2017373797B2 (enExample)
CA (1) CA3046076A1 (enExample)
MX (2) MX2019006475A (enExample)
WO (1) WO2018106693A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
CN109312338B (zh) * 2015-10-30 2022-09-27 爱迪塔斯医药公司 治疗单纯疱疹病毒的crispr/cas相关方法及组合物
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3714055A1 (en) 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materials and methods for treatment of autosomal dominant retinitis pigmentosa
WO2019118875A1 (en) * 2017-12-15 2019-06-20 Ou Li Crispr-mediated genome editing with vectors
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US12227547B2 (en) 2018-09-10 2025-02-18 The Regents Of The University Of California Modulators of CAS9 polypeptides and methods of use thereof
US20220133768A1 (en) 2019-02-25 2022-05-05 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
US20220145274A1 (en) * 2019-03-12 2022-05-12 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
US12173290B2 (en) 2019-06-28 2024-12-24 Crispr Therapeutics Ag Materials and methods for controlling gene editing
WO2021053582A1 (en) * 2019-09-18 2021-03-25 Crispr Therapeutics Ag All-in-one self inactivating crispr vectors
WO2021062201A1 (en) * 2019-09-25 2021-04-01 Spotlight Therapeutics Compositions and methods for nucleoprotein targeting and expression
EP4157903A2 (en) * 2020-05-29 2023-04-05 Regents of the University of Minnesota Copolymers for intracellular therapeutic nucleic acid payload delivery
EP4255502A4 (en) * 2020-12-03 2025-07-16 Scribe Therapeutics Inc COMPOSITIONS AND METHODS FOR TARGETING BCL11A
WO2022221741A1 (en) 2021-04-16 2022-10-20 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
WO2025179057A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California In vivo modification of cell genomes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070083A1 (en) 2013-11-07 2015-05-14 Editas Medicine,Inc. CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160097338A (ko) * 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
AU2016226077B2 (en) * 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US20190002920A1 (en) * 2015-04-30 2019-01-03 The Brigham And Women's Hospital, Inc. Methods and kits for cloning-free genome editing
US20180291372A1 (en) * 2015-05-14 2018-10-11 Massachusetts Institute Of Technology Self-targeting genome editing system
PL3298134T3 (pl) 2015-05-16 2023-09-18 Genzyme Corporation Edycja genów mutacji głęboko intronowych
WO2017136335A1 (en) * 2016-02-01 2017-08-10 The Regents Of The University Of California Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070083A1 (en) 2013-11-07 2015-05-14 Editas Medicine,Inc. CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU, K.I., et al.，"A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing."，NATURE CHEMICAL BIOLOGY，2016年09月12日，Vol.12, No.11，pp.980-987+Online Methods+Supplementary，DOI: 10.1038/nchembio.2179，[Published online]
MOORE, R., et al.，"CRISPR-based self-cleaving mechanism for cotrollable gene delivery in human cells."，NUCLEIC ACIDS RESEARCH，2014年12月18日，Vol.43, No.2，pp.1297-1303，DOI: 10.1093/nar/gku1326，[Published online]

Also Published As

Publication number Publication date
US10006054B1 (en) 2018-06-26
US20230416787A1 (en) 2023-12-28
EP3548614A1 (en) 2019-10-09
US9963719B1 (en) 2018-05-08
CN110168084A (zh) 2019-08-23
MX2019006475A (es) 2019-09-26
US11692205B2 (en) 2023-07-04
AU2017373797B2 (en) 2024-08-29
KR102604903B1 (ko) 2023-11-21
KR20190088555A (ko) 2019-07-26
US11028411B2 (en) 2021-06-08
CA3046076A1 (en) 2018-06-14
US10494649B2 (en) 2019-12-03
US20180251792A1 (en) 2018-09-06
US20220017927A1 (en) 2022-01-20
JP2019536462A (ja) 2019-12-19
MX2024002327A (es) 2024-03-07
US20180201956A1 (en) 2018-07-19
JP2023052089A (ja) 2023-04-11
US12264331B2 (en) 2025-04-01
US20200056208A1 (en) 2020-02-20
WO2018106693A1 (en) 2018-06-14
AU2017373797A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
US12264331B2 (en) Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA
JP7610559B2 (ja) 合成ガイド分子、それに関連する組成物および方法
US12359223B2 (en) Systems and methods for modulating chromosomal rearrangements
US20200299661A1 (en) Cpf1-related methods and compositions for gene editing
US11866726B2 (en) Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
JP2025011076A (ja) 高ＩｇＭ症候群を処置するためのシステム及び方法
KR20260019520A (ko) Fl1-1 발현을 표적화하는 crispr 관련 방법 및 조성물
KR20260018069A (ko) Ptpn2 발현을 표적화하는 crispr 관련 방법 및 조성물
KR20260018068A (ko) Cd70 발현을 표적화하는 crispr 관련 방법 및 조성물
NZ795268A (en) Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230427

R150 Certificate of patent or registration of utility model

Ref document number: 7272952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250